Search research articles
Contact Us
Filters
Showing results (121-130 of 179) with videos related to
Page
of 18
Sort By:
Clinical and Experimental Rheumatology
|
February 28, 2025
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol
Sharfaraz Salam, Jasper M Morrow, Michael P McDermott, et al.
Muscle & Nerve
|
March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
James F Howard, Richard J Barohn, Gary R Cutter, et al.
JAMA Neurology
|
June 26, 2013
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial
Richard A Lewis, Michael P McDermott, David N Herrmann, et al.
Muscle & Nerve
|
October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis
Gil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Journal of Clinical Neuromuscular Disease
|
August 23, 2013
Leg amyotrophic diplegia: prevalence and pattern of weakness at US neuromuscular centers
Mazen M Dimachkie, Iryna M Muzyka, Jonathan S Katz, et al.
The Lancet. Neurology
|
October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Muscle & Nerve
|
June 2, 2021
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
Carol Milligan, Nazem Atassi, Suma Babu, et al.
European Journal of Neurology
|
February 13, 2023
Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study
Mamatha Pasnoor, Vera Bril, Todd Levine, et al.
Muscle & Nerve
|
May 21, 2019
Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis
Gita Ramdharry, Jasper Morrow, Stacie Hudgens, et al.
Journal of Neuromuscular Diseases
|
November 19, 2016
A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa
Beth L Thurberg, Pierre Carlier, John T Kissel, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 179) with videos related to
Sort By:
Page
of 18
Clinical and Experimental Rheumatology
|
February 28, 2025
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol
Sharfaraz Salam, Jasper M Morrow, Michael P McDermott, et al.
Muscle & Nerve
|
March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
James F Howard, Richard J Barohn, Gary R Cutter, et al.
JAMA Neurology
|
June 26, 2013
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial
Richard A Lewis, Michael P McDermott, David N Herrmann, et al.
Muscle & Nerve
|
October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis
Gil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Journal of Clinical Neuromuscular Disease
|
August 23, 2013
Leg amyotrophic diplegia: prevalence and pattern of weakness at US neuromuscular centers
Mazen M Dimachkie, Iryna M Muzyka, Jonathan S Katz, et al.
The Lancet. Neurology
|
October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Muscle & Nerve
|
June 2, 2021
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
Carol Milligan, Nazem Atassi, Suma Babu, et al.
European Journal of Neurology
|
February 13, 2023
Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study
Mamatha Pasnoor, Vera Bril, Todd Levine, et al.
Muscle & Nerve
|
May 21, 2019
Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis
Gita Ramdharry, Jasper Morrow, Stacie Hudgens, et al.
Journal of Neuromuscular Diseases
|
November 19, 2016
A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa
Beth L Thurberg, Pierre Carlier, John T Kissel, et al.
Page
of 18